Nurix Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Nurix Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- NRIX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001549595
Board of directors
-
Anil Kapur · DirectorSince 2024
-
Arthur T. Sands · Director · President, CEOSince 2023
-
David L. Lacey · DirectorSince 2023
-
Edward C. Saltzman · DirectorSince 2023
-
Judith A. Reinsdorf · DirectorSince 2023
-
Julia P. Gregory · DirectorSince 2023
-
Lori Anne Kunkel · DirectorSince 2023
-
Paul M. Silva · DirectorSince 2023
-
Roger D. Dansey · DirectorSince 2025
-
Roy D. Baynes · DirectorSince 2025
Chief executives
Arthur T. Sands
· President, CEO
Dates unknown
Board connections
8 of this board's directors also sit on 13 other boards.
- via Roy D. Baynes
- via David L. Lacey
- via Roger D. Dansey
- via Julia P. Gregory
- via Lori Anne Kunkel
- via Judith A. Reinsdorf
- via Roger D. Dansey
- via Roy D. Baynes
- via Lori Anne Kunkel
- via Paul M. Silva
- via Judith A. Reinsdorf
- via Roy D. Baynes
- via Anil Kapur
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,344,821
- 37 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 5, 2026 | Hansen Gwenn Officer (Chief Scientific Officer) | Option exercise | +4,356 | $1.86 | $8,102 |
| Aug 5, 2026 | Hansen Gwenn Officer (Chief Scientific Officer) | Open-market sale | −4,356 | $25.00 | $108,900 |
| Aug 4, 2026 | van Houte Hans Officer (Chief Financial Officer) | Open-market sale | −1,794 | $23.89 | $42,861 |
| Aug 4, 2026 | Hansen Gwenn Officer (Chief Scientific Officer) | Open-market sale | −1,500 | $23.87 | $35,803 |
| Aug 4, 2026 | van Houte Hans Officer (Chief Financial Officer) | Open-market sale | −2,967 | $24.65 | $73,129 |
| Aug 4, 2026 | Hansen Gwenn Officer (Chief Scientific Officer) | Open-market sale | −2,611 | $24.64 | $64,339 |
| Aug 3, 2026 | Ring Christine Officer (Chief Legal Officer) | Option exercise | +5,787 | $8.72 | $50,463 |
| Aug 3, 2026 | Ring Christine Officer (Chief Legal Officer) | Open-market sale | −16,589 | $23.05 | $382,358 |
| Jul 30, 2026 | Hansen Gwenn Officer (Chief Scientific Officer) | Option exercise | +3,750 | — | — |
| Jul 30, 2026 | Ring Christine Officer (Chief Legal Officer) | Option exercise | +3,750 | — | — |
| Jul 30, 2026 | van Houte Hans Officer (Chief Financial Officer) | Option exercise | +3,750 | — | — |
| Jul 30, 2026 | Hansen Gwenn Officer (Chief Scientific Officer) | Option exercise | +2,858 | — | — |
| Jul 30, 2026 | Ring Christine Officer (Chief Legal Officer) | Option exercise | +2,858 | — | — |
| Jul 30, 2026 | van Houte Hans Officer (Chief Financial Officer) | Option exercise | +2,858 | — | — |
| Jul 30, 2026 | Hansen Gwenn Officer (Chief Scientific Officer) | Option exercise | +3,572 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.